Key Segmentation
By Drug Type
-
Gamma Hydroxybutyric Acid
-
Ketamine
-
Psilocybin
-
Lysergic Acid Diethylamide
-
MDMA
-
Dimethyltryptamine
-
Ibogaine
-
Mescaline
-
Others
By Source
-
Naturally Derived
-
Synthetic
By Application
-
Treatment Resistant Depression
-
Major Depressive Disorder
-
Post Traumatic Stress Disorder
-
Substance and Opiate Addiction
-
Anxiety and Panic Disorders
-
Narcolepsy and Sleep Disorders
-
Alcohol Use Disorder
-
Others
By Route of Administration
-
Oral
-
Intranasal
-
Intravenous
-
Sublingual and Buccal
-
Transdermal
-
Others
By End Use Setting
-
Research and Academic Institutes
-
Homecare Settings
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Ans: The Psychedelic Drugs Market is expected to grow at a CAGR of 13.68% from 2026 to 2035.
Ans: The Psychedelic Drugs Market was valued at USD 4.13 billion in 2025.
Ans: The surging global burden of mental illness and the documented failure of conventional psychiatric treatments for a large patient population, combined with expanding clinical trial evidence, evolving regulatory pathways, and growing institutional investment in psychedelic assisted therapy platforms.
Ans: The Ketamine segment dominated the Psychedelic Drugs Market in 2025, accounting for approximately 42% of total market revenue, driven by its FDA approved status and the rapid expansion of ketamine infusion clinic networks globally.
Ans: Research and Academic Institutes are expected to grow at the fastest CAGR from 2026 to 2035, driven by the expanding global pipeline of psychedelic clinical trials and growing government and institutional funding for psychedelic medicine research programs.